Alnylam Pharmaceuticals

Ultime notizie

Titoli nella lingua originale della fonte.

• Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49% (si apre in una nuova scheda)

  Simply Wall Street · 2 ott 2026

• Alnylam Pharmaceuticals, Carvana, MongoDB (si apre in una nuova scheda)

  TradingView · 30 set 2026

• Alnylam drafts football veteran Pete Shaw for heart disease education push (si apre in una nuova scheda)

  Fierce Pharma · 30 set 2026

• Down 35% This Year, Alnylam Still Has Wall Street Calling 44% Upside (si apre in una nuova scheda)

  NAI500 · 29 set 2026

• Alnylam shares drop 18% after AstraZeneca/Ionis trial failure, but outlook remains cautiously optimistic. (si apre in una nuova scheda)

  Pluang · 28 set 2026

• Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY) (si apre in una nuova scheda)

  Seeking Alpha · 28 set 2026

• 18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. (si apre in una nuova scheda)

  The Motley Fool · 28 set 2026

• Form 4 Alnylam Pharmaceuticals Inc For: 27 September By Investing.com (si apre in una nuova scheda)

  Investing.com Nigeria · 27 set 2026

• Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY) (si apre in una nuova scheda)

  Seeking Alpha · 26 set 2026

• The next Alnylam? RNAi biotech City Therapeutics files for IPO (si apre in una nuova scheda)

  Endpoints News · 25 set 2026

• Alnylam Pharmaceuticals (ALNY) Short Interest & Short Float | Updated Sep 2026 $ALNY (si apre in una nuova scheda)

  MarketBeat · 24 set 2026

• H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $455 (si apre in una nuova scheda)

  Moomoo · 21 set 2026

• Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook (si apre in una nuova scheda)

  Yahoo Finance · 20 set 2026

• Will RNAi Market Growth Change Alnylam Stock's Narrative? (si apre in una nuova scheda)

  Simply Wall Street · 20 set 2026

• Alnylam Pharmaceuticals (ALNY) Highlighted As An Oligonucleotide Therapeutics Leader Through 2035 (si apre in una nuova scheda)

  Simply Wall Street · 17 set 2026

• Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture (si apre in una nuova scheda)

  The Motley Fool · 15 set 2026

• Alnylam at Morgan Stanley conference: ttr growth offsets guidance trim (si apre in una nuova scheda)

  Investing.com · 14 set 2026

• Alnylam Pharmaceuticals (ALNY) Slides 3.99% to $247.71 as Shares Retreat From Recent Highs - Gap Fill Strategy (si apre in una nuova scheda)

  dars.gov.et · 10 set 2026

• Here’s Why Alnylam Pharmaceuticals (ALNY) Declined (si apre in una nuova scheda)

  Yahoo Finance · 10 set 2026

• Alnylam Pharmaceuticals (ALNY) Slides 3.99% to $247.71 as Shares Retreat From Recent Highs - Safe Entry Stocks (si apre in una nuova scheda)

  dars.gov.et · 10 set 2026

• Why Alnylam Pharmaceuticals (ALNY) Stock Is Down Today (si apre in una nuova scheda)

  Quiver Quantitative · 10 set 2026

• Alnylam Pharmaceuticals (ALNY) Slides 3.99% to $247.71 as Shares Retreat From Recent Highs - Moving Average Crossovers (si apre in una nuova scheda)

  dars.gov.et · 10 set 2026